Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Hepatology

• Publication date

  2005-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.JHEP.2005.05.037PMID 16168522
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection

  2004cited by this paper
• 382 In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation RTN236T in the HBV polymerase

  2004cited by this paper
• Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

  2004cited by this paper
• 57 Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy

  2004cited by this paper
• Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.

  2003cited by this paper
• Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients

  2003cited by this paper
• Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B

  2003cited by this paper
• Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

  2003cited by this paper
• Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

  2003cited by this paper
• Hepatitis B viral resistance: mechanisms and diagnosis.

  2003cited by this paper
• Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

  2003cited by this paper
• Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

  2003cited by this paper
• Histological outcome during long-term lamivudine therapy.

  2003cited by this paper
• Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay

  2002cited by this paper
• Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy

  2001cited by this paper
• Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy

  2001cited by this paper
• Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e Antigen–negative patients receiving lamivudine therapy

  2000cited by this paper
• The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B

  2000cited by this paper
• Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

  2000cited by this paper
• Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants

  2000cited by this paper
• Different hepatitis b virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion

  1999cited by this paper
• Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.

  1998cited by this paper
• Identification and characterization of mutations in hepatitis B virus resistant to lamivudine

  1998cited by this paper

• Viral rebound occurrence immediately after drug discontinuation involving neither drug resistance nor latent reservoir.

  2024cites this paper
• Evidence of Residual Ongoing Viral Replication in Chronic Hepatitis B Patients Successfully Treated with Nucleos(t)ide Analogues.

  2022cites this paper
• Synthesis, Anticancer and Antiviral Activity Studies of 1,3,4-Oxadiazoles: A Review

  2022cites this paper
• Drugs Resistance Against Viral Diseases

  2021cites this paper
• Unsuppressed viral load after intensive adherence counselling in rural eastern Uganda; a case of Kamuli district, Uganda

  2021cites this paper
• Emerging Role of Interleukins for the Assessment and Treatment of Liver Diseases.

  2021cites this paper
• Emergent liver transplantation for patients with acute-on-chronic liver failure.

  2021cites this paper
• Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients

  2020cites this paper
• E cacy of Different Nucleoside Analog Rescue Therapies for Entecavir-Resistant Chronic Hepatitis B Patients

  2020cites this paper
• Model for End‐Stage Liver Disease With Additional Criteria to Predict Short‐Term Mortality in Severe Flares of Chronic Hepatitis B

  2019cites this paper
• Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

  2018cites this paper
• Molecular Virology and Life Cycle

  2018cites this paper
• Genotypic Assays for Monitoring Drug Resistance in HIV-1 Infection and for Other Chronic Viral Diseases

  2017cites this paper
• Anti–Hepatitis Virus Agents

  2017cites this paper
• Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients.

  2017cites this paper
• Antiviral therapy of chronic hepatitis

  2017cites this paper
• Emerging drugs for hepatitis

  2017cites this paper
• Hepatitis B: 50 years after the discovery of Australia antigen.

  2016cites this paper
• KASL clinical practice guidelines: management of chronic hepatitis B

  2016cites this paper
• Treatment for hepatitis B in patients with drug resistance.

  2016cites this paper
• Antiviral Efficacy of Entecavir versus Entecavir plus Adefovir for Hepatitis B Virus rtA181V/T Mutants Alone

  2016cites this paper
• Small Surface Antigen Variants of HBV Associated with Responses to Telbivudine Treatment in Chronic Hepatitis B Patients

  2016cites this paper
• Comparison of the efficacy of tenofovir monotherapy versus tenofovir-based combination therapy in adefovir-experienced chronic hepatitis B patients: a systematic review and meta-analysis.

  2015cites this paper
• Antiviral therapies and prospects for a cure of chronic hepatitis B.

  2015cites this paper
• Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.

  2015cites this paper
• Hepatitis B virus reactivation with a rituximab-containing regimen.

  2015cites this paper
• EFFICACY OF TENOFOVIR AS FIRST-LINE ANTIVIRAL THERAPY IN CHRONIC HEPATITIS B INFECTION.

  2015cites this paper
• Characterization of the Cytotoxic Activity ODE-adefovir in AML

  2015cites this paper
• Adefovir dipivoxil for adults with lamivudine‐resistant chronic hepatitis B virus infection

  2015cites this paper
• Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance.

  2014cites this paper
• Effective compounds screening from Rabdosia serra (Maxim) Hara against HBV and tumor in vitro.

  2014cites this paper
• Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen‐positive, lamivudine‐resistant chronic hepatitis B

  2014cites this paper
• Molecular diagnosis and treatment of drug-resistant hepatitis B virus.

  2014cites this paper
• Mechanisms of Hepatitis B Virus Resistance Development

  2014cites this paper
• TOPIC HIGHLIGHT

  2014cites this paper
• BACKGROUND TO THE DEVELOPMENT OF ANTIVIRAL DRUG RESISTANCE

  2014cites this paper
• Management of chronic hepatitis B in severe liver disease.

  2014cites this paper
• HBV Therapy and the Problem of Drug Resistance

  2014cites this paper
• Management of antiviral drug resistance in chronic hepatitis B.

  2014cites this paper
• Mutation analysis of hepatitis B virus reverse transcriptase region among untreated chronically infected patients in Ahvaz city (South-West of Iran).

  2013cites this paper
• HBV Induced HCC: Major Risk Factors from Genetic to Molecular Level

  2013cites this paper
• Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance

  2013cites this paper
• The short-term efficacy of entecavir in lamivudine-resistant chronic hepatitis B: influence of sequential adefovir-refractoriness.

  2013cites this paper
• Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

  2012cites this paper
• Management of treatment failure in chronic hepatitis B.

  2012cites this paper
• Maternal-Fetal Transmission of HBV

  2012cites this paper
• Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

  2012cites this paper
• Hepadnaviruses and Hepatocellular Carcinoma

  2012cites this paper
• KASL Clinical Practice Guidelines: Management of chronic hepatitis B

  2012cites this paper
• Role of Resistance Testing During Oral Antiviral Therapy of Chronic Hepatitis B

  2012cites this paper
• Treatment of special populations with chronic hepatitis B infection

  2011cites this paper
• The influence of hepatitis B virus genotypes

  2011cites this paper
• Synthesis and biological evaluation of Matijing-Su derivatives as potent anti-HBV agents.

  2011cites this paper
• Four‐year study of lamivudine and adefovir combination therapy in lamivudine‐resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern

  2011cites this paper
• Management of chronic hepatitis B

  2011cites this paper
• The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma

  2011cites this paper
• Drug Safety Evaluation Safety evaluation of telbivudine

  2011cites this paper
• The Level of HBV DNA at Month 12 Is an Important Predictor of Virological Breakthrough During Adefovir Monotherapy in Chronic Hepatitis B Patients with Lamivudine Resistance

  2011cites this paper
• [Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B].

  2011cites this paper
• Characterization of hepatitis virus B isolated from a multi-drug refractory patient.

  2011cites this paper
• Long‐term efficacy of entecavir in adefovir‐refractory chronic hepatitis B patients with prior lamivudine resistance

  2011cites this paper
• Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B.

  2011cites this paper
• Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites

  2011cites this paper
• La respuesta virológica al tratamiento con adefovir dipivoxil predice el desarrollo de resistencias a largo plazo en pacientes con hepatitis crónica B HBeAg negativo previamente no tratados

  2011cites this paper
• Hepatitis B resistance in Iran.

  2010influential citation
• The Hong Kong Medical Diary

  2010cites this paper
• Adefovir plus lamivudine are more effective than adefovir alone in lamivudine‐resistant HBeAg‐ chronic hepatitis B patients: A 4‐year study

  2010cites this paper
• [Analogs combination therapy in chronic hepatitis B: when and how?].

  2010cites this paper
• Antiviral drug resistance: mechanisms and clinical implications.

  2010cites this paper
• Safety evaluation of telbivudine

  2010cites this paper
• Response to Adefovir Depends on Mutation Patterns in Precore Region, Basal Core Promoter and Reverse Transcriptase, and On-Treatment Responses in Lamivudine-Resistant Chronic Hepatitis B Patients

  2010cites this paper
• Optimizing Treatment Strategies Using Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B

  2010cites this paper
• Viral Infections by Nonhepatotropic Viruses

  2010cites this paper
• A low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B.

  2010cites this paper
• 13 Résultats des essais thérapeutiques dans l’hépatite chronique B

  2010cites this paper
• The mechanism and treatment of anti-viral resistant hepatitis B virus

  2010cites this paper
• Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B

  2010cites this paper
• Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B

  2010cites this paper
• Antiviral drug resistance: mechanisms and clinical implications.

  2010cites this paper
• Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium

  2010influential citation
• rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B

  2010cites this paper
• Rituximab Administration and Reactivation of HBV

  2010cites this paper
• Bithérapie par analogues dans le traitement de l’hépatite chronique B : de novo ou en cas d’échec

  2010cites this paper
• Kosteneffectiviteit van antivirale behandeling voor chronische hepatitis B in België

  2010influential citation
• Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines.

  2010cites this paper
• Mechanistic Characterization and Molecular Modeling of Hepatitis B Virus Polymerase Resistance to Entecavir

  2010cites this paper
• La résistance du VHB aux analogues nucléos(t)idiques

  2010cites this paper
• Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.

  2010cites this paper
• Drug resistance in antiviral therapy.

  2010cites this paper
• Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections

  2010cites this paper
• Pathobiology of HBV mutants and clinical impact for treatment monitoring

  2009cites this paper
• Monotherapy versus combination therapy for the treatment of chronic hepatitis B

  2009cites this paper
• On‐treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks

  2009cites this paper
• Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy

  2009cites this paper
• Does RNA interference provide new hope for control of chronic hepatitis B infection?

  2009cites this paper
• Hepatitis B: the case for combination therapy.

  2009cites this paper
• Chronic hepatitis B: Update 2009

  2009cites this paper
• Hepatitis B Virus

  2009cites this paper
• ラミブジン耐性B型肝硬変に対しアデフォビル併用療法を開始し，4年後にアデフォビル耐性遺伝子変異によるbreakthrough hepatitisを認めた1例

  2009cites this paper
• Prevention of hepatitis B virus reactivation under rituximab therapy.

  2009cites this paper